RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Abcellera Biologics Stock

Abcellera Biologics Stocks 2024

Abcellera Biologics Stocks

289.17 M

Ticker

ABCL

ISIN

CA00288U1066

WKN

A2QKXS

In 2024, Abcellera Biologics had 289.17 M outstanding stocks, a 0% change from the 289.17 M stocks in the previous year.

The Abcellera Biologics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e289.17
2029e289.17
2028e289.17
2027e289.17
2026e289.17
2025e289.17
2024e289.17
2023289.17
2022314.8
2021318.3
2020269.5
2019265.6
2018265.6

Abcellera Biologics shares outstanding

The number of shares was Abcellera Biologics in 2023 — This indicates how many shares 289.167 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Abcellera Biologics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Abcellera Biologics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Abcellera Biologics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Abcellera Biologics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Abcellera Biologics Aktienanalyse

What does Abcellera Biologics do?

Abcellera Biologics Inc. is a leading biotechnology company specializing in the discovery of antibodies and the identification of therapies for serious diseases. The company was founded in Vancouver, Canada in 2012 and has since become a major player in the biotechnology field. It has formed numerous significant partnerships with large pharmaceutical companies in recent years and works closely with leading universities and research institutions worldwide. Abcellera Biologics Inc. follows a new, innovative business model that focuses on the discovery of antibodies through the application of cutting-edge technologies, data science, and machine learning. The company has developed a revolutionary technology platform called "Microfluidic Drop-based Technology" that is capable of discovering thousands of antibodies within just a few weeks. This technology allows for the rapid and efficient discovery of antibodies that can be used in the treatment of serious diseases. Abcellera Biologics Inc. is divided into several divisions that focus on antibody discovery, therapy development, collaborations with pharmaceutical companies, and services. Antibody discovery is carried out through years of research and development using state-of-the-art technologies and methods. Therapy development includes preclinical and clinical development of therapeutic products and conducting clinical trials. Abcellera Biologics Inc. works closely with leading pharmaceutical companies in the industry to develop new therapies and discover antibodies. The company has already formed numerous partnerships with major pharmaceutical companies such as Pfizer, Sanofi, GlaxoSmithKline, AbbVie, and Biogen. Another important focus of Abcellera Biologics Inc. is providing services in the field of antibody development. The company has extensive expertise in antibody discovery and therefore offers services to other companies. This allows other companies to benefit from Abcellera Biologics Inc.'s unique technology platform and top-notch capabilities. Abcellera Biologics Inc.'s product portfolio includes various antibody therapies targeting the treatment of specific diseases. One of the company's most promising products is the "LY-CoV555" antibody therapy used for COVID-19. This therapy was developed in collaboration with Eli Lilly and is currently being tested in clinical trials. Overall, Abcellera Biologics Inc. has become a leading company in the biotechnology industry. Its focus on antibody discovery through state-of-the-art technologies and data-driven methods, as well as successful collaborations with major pharmaceutical companies, makes it an important player in the industry. Abcellera Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Abcellera Biologics's Shares Outstanding

Abcellera Biologics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Abcellera Biologics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Abcellera Biologics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Abcellera Biologics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Abcellera Biologics stock

How many stocks are there of Abcellera Biologics?

The current number of stocks of Abcellera Biologics is 289.17 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Abcellera Biologics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Abcellera Biologics evolved in recent years?

The number of shares of Abcellera Biologics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Abcellera Biologics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Abcellera Biologics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Abcellera Biologics pay?

Over the past 12 months, Abcellera Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abcellera Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of Abcellera Biologics?

The current dividend yield of Abcellera Biologics is .

When does Abcellera Biologics pay dividends?

Abcellera Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abcellera Biologics?

Abcellera Biologics paid dividends every year for the past 0 years.

What is the dividend of Abcellera Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abcellera Biologics located?

Abcellera Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abcellera Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abcellera Biologics from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Abcellera Biologics pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Abcellera Biologics in the year 2023?

In the year 2023, Abcellera Biologics distributed 0 USD as dividends.

In which currency does Abcellera Biologics pay out the dividend?

The dividends of Abcellera Biologics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abcellera Biologics

Our stock analysis for Abcellera Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abcellera Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.